Induction of c-Jun Expression by Breast Cancer Anti-estrogen Resistance-3 (BCAR3) in Human Breast MCF-12A Cells

국문 초록 (Abstract)

타목시펜과 같은 항에스트로젠은 ER 양성의 초기 유방암 환자에게 사용되고 있다. 그러나 대부분의 환자에서 이 항에스트로젠에 대한 내성 발현은 불가피하게 발생한다. BCAR3 유전자는 사람의 에스트로젠 의존성 유방암에서 tamoxifen 내성유도를 야기하는 단백질로 발견되었다. 우리들은 이전에 이 BCAR3 유전자가 세포주기 진행과 EGF와 인슐린에 의한 DNA 합성 신호전달경로를 조절한다고 보고하였다. 본 연구에서는, 비종양성 정상적인 인간유방상피세포인 MCF-12A세포에서 c-Jun 전자의 조절에 대한 BCAR3유전자의 기능적인 역할을 조사하였다. BCAR3의 일시적인 발현 또는 지속적인 발현이 c-Jun mRNA와 단백질의 발현을 증가하는 것을 발견하였다. 또한 BCAR3 발현 유전자의 미세주사에 의해 세포 증식이 증가하였다. 이 c-Jun의 발현 증가는 promoter의 활성화를 통해 일어난다. 또한 BCAR3에 의한 c-Jun 발현 유도가 억제성 Ras, Rac, Rho에 의해 억제되었다. 다음으로 EGF 성장인자에 의한 c-Jun 발현 유도에 대한 BCAR3의 영향을 단일 세포 미세주사법에 의해 조사하였다. BCAR3 항체, BCAR3의 siRNA와 같은 BCAR3의 기능을 억제할 수 있는 물질들을 세포로 미세주사하면 EGF에 의한 c-Jun의 발현을 억제하였지만, IGF-1 성장인자에 의한 c-Jun 발현은 억제하지 않았다. 이러한 결과들로부터 BCAR3는 c-Jun 단백질 발현 유도와 세포 증식에 중요한 역할을 하며, 여기에는 Ras, Rac, Rho와 같은 GTPase들이 필요하다는 것을 발견하였다.

다국어 초록 (Multilingual Abstract)

Anti-estrogen drugs such as tamoxifen have been used for treating patients with ER-positive, early breast cancer. However, resistance to anti-estrogen treatment is inevitable in most patients. Breast cancer anti-estrogen resistance-3 (BCAR3) has been identified as the protein responsible for the induction of tamoxifen resistance in estrogen-dependent human breast cancer. We have previously reported that BCAR3 regulates the cell cycle progression and the signaling pathway of EGF and insulin leading to DNA synthesis. In this study, we investigated the functional role of BCAR3 in regulating c-Jun transcription in non-tumorigenic human breast epithelial MCF-12A cells. A transient transfection of BCAR3 increased both the mRNA and protein of c-Jun expression, and stable expression of BCAR3 increased c-Jun protein expression. The overexpression of BCAR3 directly activated the promoter of c-jun, AP-1, and SRE but not that of NF-κB. Furthermore, single-cell microinjection of BCAR3 expression plasmid in the cell cycle-arrested MCF-12A cells induced c-Jun protein expression, and co-injection of dominant negative mutants of Ras, Rac, and Rho suppressed the transcriptional activity of c-Jun in the presence of BCAR3. Furthermore, stable expression of BCAR3 increased the proliferation of MCF-12A cells. The microinjection of inhibitory materials such as anti-BCAR3 antibody and siRNA BCAR3 inhibited EGF-induced c-Jun expression but did not affect IGF-1 induced upregulation of c-Jun. Taken together, we propose that BCAR3 plays a crucial role in c-Jun protein expression and cell proliferation and that small GTPases (e.g., Ras, Rac, and Rho) are required for the BCAR3-mediated activation of c-Jun expression.

목차 (Table of Contents)

• Introduction
• Materials and Methods
• Results
• Discussion
• References
• 초록

참고문헌 (Reference)

1 Gotoh, T., "p130Cas regulates the activity of AND-34, a novel Ral, Rap1, and R-Ras guanine nucleotide exchange factor" 275 : 30118-30123, 2000

2 Smith, L. M., "cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype" 18 : 6063-6070, 1999

3 Meng, Q., "c-Jun, at the crossroad of the signaling network" 2 : 889-898, 2011

4 Vleugel, M. M., "c-Jun activation is associated with proliferation and angiogenesis in invasive breast cancer" 37 : 668-674, 2006

5 Alani, R., "The transactivating domain of the c-Jun proto-oncoprotein is required for cotransformation of rat embryo cells" 11 : 6286-6295, 1991

6 Domann, F. E., "Stable expression of a c-JUN deletion mutant in two malignant mouse epidermal cell lines blocks tumor formation in nude mice" 5 : 9-16, 1994

7 Early Breast Cancer Trialists' Collaborative, "Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials" 378 : 771-784, 2011

8 van Agthoven, T., "Protein pathway activation mapping reveals molecular networks associated with antiestrogen resistance in breast cancer cell lines" 131 : 1998-2007, 2012

9 Schiff, R., "Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo" 92 : 1926-1934, 2000

10 Mace, P. D., "NSP-Cas protein structures reveal a promiscuous interaction module in cell signaling" 18 : 1381-1387, 2011

11 Pietras, R. J, "Interactions between estrogen and growth factor receptors in human breast cancers and the tumor- associated vasculature" 9 : 361-373, 2003

12 Ibrahim, Y. H., "Insulin-like growth factor-I and cancer risk" 14 : 261-269, 2004

13 Boyd, D. B, "Insulin and cancer" 2 : 315-329, 2003

14 Xu, Y., "Inhibition of proliferation of estrogen receptor positive MCF7 human breast cancer cells by tamoxifen through cJun transcription factors" 7 : 1283-1287, 2013

15 van Agthoven, T., "Identification of BCAR3 by a random search for genes involved in antiestrogen resistance of human breast cancer cells" 17 : 2799-2808, 1998

16 Zhao, C., "Genome-wide profiling of AP-1-regulated transcription provides insights into the invasiveness of triple-negative breast cancer" 74 : 3983-3994, 2014

17 Oh, M. J., "Functional roles of BCAR3 in the signaling pathways of insulin leading to DNA synthesis, membrane ruffling and GLUT4 translocation" 441 : 911-916, 2013

18 Babu, R. L., "Effect of estrogen and tamoxifen on the expression pattern of AP-1 factors in MCF-7 cells: role of c-Jun, c-Fos, and Fra-1 in cell cycle regulation" 380 : 143-151, 2013

19 Lo, H. W., "EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization" 95 : 211-218, 2006

20 Zhang, Y., "Critical role of c-Jun overexpression in liver metastasis of human breast cancer xenograft model" 7 : 145-, 2007

21 Johnson, R., "Cellular transformation and malignancy induced by ras require c-jun" 16 : 4504-4511, 1996

22 Schrecengost, R. S., "Breast cancer antiestrogen resistance-3 expression regulates breast cancer cell migration through promotion of p130Cas membrane localization and membrane ruffling" 67 : 6174-6182, 2007

23 Cross, A. M., "Breast cancer antiestrogen resistance 3-p130Cas interactions promote adhesion disassembly and invasion in breast cancer cells" 2016

24 Wilson, A. L., "Breast cancer antiestrogen resistance 3 (BCAR3) promotes cell motility by regulating actin cytoskeletal and adhesion remodeling in invasive breast cancer cells" 8 : e65678-, 2013

25 Oh, M. J., "BCAR3 regulates EGF-induced DNA synthesis in normal human breast MCF-12A cells" 375 : 430-434, 2008

26 Wallez, Y., "Association of the breast cancer antiestrogen resistance protein 1(BCAR1) and BCAR3 scaffolding proteins in cell signaling and antiestrogen resistance" 289 : 10431-10444, 2014

27 Shaulian, E., "AP-1 as a regulator of cell life and death" 4 : E131-E136, 2002

28 Cai, D., "AND-34/BCAR3, a GDP exchange factor whose overexpression confers antiestrogen resistance, activates Rac, PAK1, and the cyclin D1 promoter" 63 : 6802-6808, 2003

29 Near, R. I., "AND-34/BCAR3 differs from other NSP homologs in induction of anti-estrogen resistance, cyclin D1promoter activation and altered breast cancer cell morphology" 212 : 655-665, 2007

30 Felekkis, K. N., "AND-34 activates phosphatidylinositol 3-kinase and induces anti-estrogen resistance in a SH2 and GDP exchange factor-like domain-dependent manner" 3 : 32-41, 2005